What Monticola Provides
Our Services
Proven Success: Delivering Results
Monticola is proud to have contributed to UNP’s $1.5B multi-target transaction with argenx in July of 2025. In 2024, Monticola closed 4 transactions, including leading a $900M deal between Sutro Biopharma and Ipsen for a preclinical-stage ROR1-ADC in solid tumors. Currently, we are supporting several clients in high-value, risk-sharing negotiations with Big Pharma, including:
● Licensing agreements
● Research collaborations
● Co-development and co-commercialization deals
● Equity purchases
These agreements are designed to drive growth, enhance innovation and capability building, and establish precedents that will help our clients achieve future success.
Monticola works under a monthly retainer and success fee structure that is negotiated on a client by client and project by project basis.
